Drug intelligence / Profile preview

aftobetin

Development stage: Phase 1
Lead developer: Cognoptix
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

Aftobetin (also known as aftobetin hydrochloride) is a small molecule fluorescent ligand developed by Cognoptix for the early detection of Alzheimer's disease. It is the pharmaceutical component of the SAPPHIRE II system, a drug-device combination. Aftobetin is applied topically as an ophthalmic ointment, where it penetrates the eye and binds specifically to beta-amyloid protein aggregates in the lens. The SAPPHIRE II laser scanner then measures the fluorescence emitted by the bound ligand to quantify amyloid levels, which serve as a biomarker for Alzheimer's pathology. The technology was licensed from Massachusetts General Hospital and Brigham & Women's Hospital.

Other names: aftobetin hydrochlorideaftobetin-HCl

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on aftobetin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aftobetin.

Explore the full profile